Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 713.01% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 1444.72% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 794.31% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 1363.41% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 469.11% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 3152.03% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1769.92% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1932.52% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/26/2023 | 713.01% | HC 溫賴特 & 有限公司. | 十九元 → 十美元 | 維護 | 購買 |
| 2022 年 8 月 16 日 | — | 美心集團 | 降級 | 購買 → 持有 | |
| 07/20/2021 | 1444.72% | HC 溫賴特 & 有限公司. | 十一美元 → 十九美元 | 維護 | 購買 |
| 05/15/2020 | 794.31% | HC 溫賴特 & 有限公司. | 7 美元 → 11 美元 | 重申 | → 購買 |
| 02/19/2020 | 1363.41% | 羅斯資本 | → 18 美元 | 啟動覆蓋範圍 | → 購買 |
| 12/30/2019 | 469.11% | HC 溫賴特 & 有限公司. | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
| 09/10/2018 | 3152.03% | 北海岸研究 | → 40 美元 | 啟動覆蓋範圍 | → 跑贏大市 |
| 09/10/2018 | 1769.92% | 萊德洛 & 有限公司. | → 二十三美元 | 啟動覆蓋範圍 | → 購買 |
| 09/10/2018 | 1932.52% | 康托·菲茨杰拉德 | → 25 美元 | 啟動覆蓋範圍 | → 超重 |
What is the target price for Aridis Pharmaceuticals (ARDS)?
阿里迪斯製藥（ARDS）的目標價格是多少？
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $10.00 expecting ARDS to rise to within 12 months (a possible 713.01% upside). 2 analyst firms have reported ratings in the last year.
HC 溫萊特有限公司於 2023 年 1 月 26 日報導了阿里迪斯製藥公司（納斯達克股票代碼：ARDS）的最新價格目標。該分析師公司設定了 10.00 美元的價格目標，預計 ARDS 將在 12 個月內上升（可能有 713.01％ 的上行情況）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
阿里迪斯製藥（ARDS）的最新分析師評級是什麼？
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals maintained their buy rating.
阿里迪斯製藥公司（NASDAQ：ARDS）的最新分析師評級由 HC 溫賴特公司提供，而阿里迪斯製藥保持其購買評級。
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
Aridis 製藥（ARDS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析師在進行了廣泛的研究後抵達股票評級，其中包括通過公共財務報表，與 Aridis 藥品的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。對於阿里迪斯製藥的最後評級提交了一月 26, 2023 所以你應該期望下一個評級將在一月左右的某個時候提供 26, 2024.
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
分析師評級阿里迪斯製藥（ARDS）是否正確？
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a maintained with a price target of $19.00 to $10.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $1.23, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的阿里迪斯製藥（ARDS）評級維持，目標價格為 19.00 美元至 10.00 美元。當前價格阿里迪斯製藥（ARDS）的交易價格為 1.23 美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。